Bowling Portfolio Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bowling Portfolio Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,537	Closed	-$494K	–	403
2019 Q2	$494K	Buy	+20,537	New	+$521K	0.08%	270
2018 Q3	–	Sell	-63,897	Closed	-$1.06M	–	396
2018 Q2	$1.06M	Buy	+63,897	New	+$974K	0.15%	224
2017 Q3	–	Sell	-14,036	Closed	-$167K	–	439
2017 Q2	$167K	Sell	14,036 -27,647	-66%	-$344K	0.02%	356
2017 Q1	$616K	Buy	+41,683	New	+$675K	0.1%	249

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bowling Portfolio Management's HZNP Position: Q3 2019 in Review

Bowling Portfolio Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2019, closing a stake of 20,537 shares — an estimated $494K sold.

Bowling Portfolio Management first reported a position in HZNP in Q1 2017 and held it in 4 quarters. The position peaked at $1.06M in Q2 2018. 264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

Bowling Portfolio Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2019 after selling out during the quarter.
Bowling Portfolio Management sold 20,537 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2019, an estimated $494K.
Bowling Portfolio Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and held it in 4 quarters.
Bowling Portfolio Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.06M in Q2 2018.
264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on Bowling Portfolio Management's 13F filing for Q3 2019, filed 15 Oct 2019.